MISSISSAUGA, ON, Oct. 21, 2011 /PRNewswire/ - Covalon Technologies Ltd. (the
"Company" or "Covalon") (TSXV: COV), an advanced medical technologies
company, today announced it will be presenting SurgiClear, its new
breakthrough surgical wound care product at this year's American
College of Surgeons Clinical Congress (ACS), running October 23 to 27,
2011 in San Francisco.
SurgiClear is a clear film dressing with a breakthrough antimicrobial
silicone adhesive especially designed to reduce the instances of
surgical site infections.
Surgical site infections occur when germs enter the body through the
incision site after a surgical procedure. Treating surgical site
infections is a costly burden to the healthcare system and can cause
serious, and in certain cases, life-threatening complications for
patients. According to the Journal of Infection Control and Hospital
Epidemiology, treating surgical site infections accounts for up to $10
billion annually in healthcare expenditures in the United States alone.
SurgiClear is the first transparent film dressing that allows clinicians
and patients to monitor the healing process of surgical sites while
providing effective antimicrobial protection for up to seven days
against the leading organisms that cause surgical site infections, with
the aid of two antimicrobial compounds infused directly into the
"We are extremely excited to showcase SurgiClear at this year's ACS
meeting," said Brian Pedlar, Covalon's Chief Executive Officer. "There
has been great excitement and interest about SurgiClear from surgeons,
and medical device companies who are looking to license breakthrough
To learn more about Covalon's products and services, please visit us at
booth 1938 in the San Francisco Moscone Convention Centre from October
23 to 27 or contact Brian Pedlar, CEO Covalon Technologies Ltd. at email@example.com.
Covalon Technologies Ltd. researches, develops and commercializes new
healthcare technologies that help save lives around the world.
Covalon's patented technologies, products and services address the
advanced healthcare needs of medical device companies, healthcare
providers and individual consumers. Covalon's technologies are used to
prevent, detect and manage medical conditions in specialty areas such
as wound care, tissue repair, infection control, disease management,
medical device coatings and biocompatibility. To learn more about
Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will",
"should", "could" or "might" occur or be achieved and other similar
expressions. These forward-looking statements involve risk and
uncertainties, including the difficulty in predicting product
approvals, acceptance of and demands for new products, the impact of
the products and pricing strategies of competitors, delays in
developing and launching new products, the regulatory environment,
fluctuations in operating results and other risks, any of which could
cause results, performance, or achievements to differ materially from
the results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific to
the Company. Investors should consult the Company's ongoing quarterly
filings for additional information on risks and uncertainties relating
to these forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements whether as
a result of new information, further events or otherwise.
SOURCE Covalon Technologies Ltd.